Yamamoto Toru, Fujii-Abe Keiko, Fukayama Haruhisa, Kawahara Hiroshi
Section of Anesthesiology and Clinical Physiology, Department of Oral Restitution, Division of Oral Health Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, and.
Department of Dental Anesthesiology, Tsurumi University School of Dental Medicine, Yokohama, Japan.
Anesth Prog. 2018 Summer;65(2):76-81. doi: 10.2344/anpr-65-02-03.
We retrospectively investigated the efficacy and safety of propofol administration alone and in combination with midazolam for gag reflex suppression during dental treatment under intravenous sedation. We included 56 patients with an overactive gag reflex who were to undergo dental treatment under intravenous sedation. They were divided into propofol (P group, n = 22) and midazolam with propofol (MP group, n = 34) groups. The P group received propofol alone, while the MP group received midazolam (0.04 mg/kg) prior to target-controlled infusion (TCI) of propofol (titrated for adequate sedation). The patients' anesthetic records were evaluated for vital sign changes, adverse cardiovascular or respiratory event frequency, the number of forced treatment interruptions, and the TCI-predicted cerebral propofol concentration at gag reflex suppression (posterior tongue stimulation with a dental mirror). No significant differences were observed between the 2 groups preoperatively. There were no cases of forced interruptions or significant respiratory compromise in either group. Cardiovascular adverse event frequency was lower in the MP group than in the P group (all p < .05). Our results suggest that propofol, when combined with midazolam, minimized cardiovascular effects compared with propofol alone when used to suppress the gag reflex in patients during dental treatment under intravenous sedation.
我们回顾性研究了在静脉镇静下牙科治疗期间单独使用丙泊酚以及丙泊酚与咪达唑仑联合使用对抑制咽反射的有效性和安全性。我们纳入了56例咽反射亢进且拟接受静脉镇静下牙科治疗的患者。他们被分为丙泊酚组(P组,n = 22)和丙泊酚联合咪达唑仑组(MP组,n = 34)。P组仅接受丙泊酚,而MP组在丙泊酚靶控输注(TCI)(根据镇静程度进行滴定)前接受咪达唑仑(0.04 mg/kg)。评估患者的麻醉记录,包括生命体征变化、心血管或呼吸不良事件发生频率、强制治疗中断次数以及咽反射抑制时(用牙镜刺激舌根)TCI预测的丙泊酚脑浓度。两组术前未观察到显著差异。两组均无强制中断治疗或严重呼吸功能不全的病例。MP组心血管不良事件发生频率低于P组(所有p <.05)。我们的结果表明,在静脉镇静下牙科治疗期间用于抑制患者咽反射时,与单独使用丙泊酚相比,丙泊酚与咪达唑仑联合使用可将心血管效应降至最低。